Human Anti-GUCY2C Recombinant Antibody (
2E5) (V2LY-0725-LY739)

Name: Human Anti-GUCY2C Recombinant Antibody (2E5)
SKU: V2LY-0725-LY739
Rating: 5 (1 reviews)

See all GUCY2C antibodies

Compare Online Inquiry

Tested Data

Human Anti-GUCY2C Recombinant Antibody (2E5) (V2LY-0725-LY739) in ELISA

The Binding Activity of Human GUCY2C with Anti-GUCY2C recombinant antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Human GUCY2C at 5 μg/mL can bind Anti-GUCY2C recombinant antibody, the EC50 is 5.630-9.996 ng/mL.

Human Anti-GUCY2C Recombinant Antibody (2E5) (V2LY-0725-LY739) in FC

T84 cells were stained with Human IgG (green line) and anti-GUCY2C antibody (red line) (2µg/1*106cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.

Human Anti-GUCY2C Recombinant Antibody (2E5) (V2LY-0725-LY739) in FC

Untransfected CT26 cells surface (green line) and transfected Human GUCY2C CT26 stable cells surface (red line) were stained with anti-GUCY2C antibody (2µg/1*106cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Human

Clone

2E5

Application

ELISA, FC

Immunogen

Recombinant Human GUCY2C protein.

Host Species

Human

Specificity

Human

Antibody Isotype

IgG1

Clonality

Monoclonal Antibody

Application Notes

Application	Note
FC	1:50-1:200

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS, Glycerol

Preservative

Sodium azide

Concentration

Batch dependent

Purity

> 95% Purity determined by SDS-PAGE.

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

More Infomation

Target

Full Name

guanylate cyclase 2C (heat stable enterotoxin receptor)

Entrez Gene ID

2984

UniProt ID

P25092

Function

Guanylyl cyclase that catalyzes synthesis of cyclic GMP (cGMP) from GTP (PubMed:1718270, PubMed:11950846, PubMed:23269669, PubMed:22521417, PubMed:22436048).

Receptor for the E.coli heat-stable enterotoxin; E.coli enterotoxin markedly stimulates the accumulation of cGMP in mammalian cells expressing GUCY2C (PubMed:1718270, PubMed:1680854).

Also activated by the endogenous peptides guanylin and uroguanylin (PubMed:8381596).

Biological Process

cGMP biosynthetic process Source: GO_Central
Intracellular signal transduction Source: InterPro
Receptor guanylyl cyclase signaling pathway Source: GO_Central
Regulation of cell population proliferation Source: Ensembl
Response to toxic substance Source: Ensembl
Signal transduction Source: GO_Central

Cellular Location

Cell membrane; Endoplasmic reticulum membrane. The 145 kDa plasma membrane form of GUCY2C contains sialic acid and galactose residues, while a differencially glycosylated 130 Kda form is a high mannose form that is resident in the endoplasmic reticulum and may serve as the precursor for the cell surface form.

Involvement in disease

Diarrhea 6 (DIAR6):
A relatively mild, early-onset chronic diarrhea that may be associated with increased susceptibility to inflammatory bowel disease, small bowel obstruction, and esophagitis.
Meconium ileus (MECIL):
A condition characterized by intestinal obstruction due to inspissated meconium in the distal ileum and cecum, which develops in utero and presents shortly after birth as a failure to pass meconium. Meconium ileus is a known clinical manifestation of cystic fibrosis.

Topology

Extracellular: 24-430
Helical: 431-454
Cytoplasmic: 455-1073

PTM

Glycosylation at Asn-75 and/or Asn-79 is required for interaction with VIP36 while glycosylation at Asn-345 and Asn-402 modulates ligand-mediated GUCY2C activation.

Barton, J. R., Londregran, A. K., Alexander, T. D., Entezari, A. A., Bar-Ad, S., Cheng, L., ... & Waldman, S. A. (2023). Intestinal neuropod cell GUCY2C regulates visceral pain. The Journal of Clinical Investigation, 133(4).

Rappaport, J. A., Entezari, A. A., Caspi, A., Caksa, S., Jhaveri, A. V., Stanek, T. J., ... & Waldman, S. A. (2022). A β-catenin-TCF-sensitive locus control region mediates GUCY2C ligand loss in colorectal cancer. Cellular and Molecular Gastroenterology and Hepatology, 13(4), 1276-1296.

Lisby, A. N., Flickinger Jr, J. C., Bashir, B., Weindorfer, M., Shelukar, S., Crutcher, M., ... & Waldman, S. A. (2021). GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert review of precision medicine and drug development, 6(2), 117-129.

Mishra, V., Bose, A., Kiran, S., Banerjee, S., Shah, I. A., Chaukimath, P., ... & Visweswariah, S. S. (2021). Gut-associated cGMP mediates colitis and dysbiosis in a mouse model of an activating mutation in GUCY2C. Journal of Experimental Medicine, 218(11).

van Vugt, A. H., Bijvelds, M. J., de Jonge, H. R., Meijsen, K. F., Restin, T., Bryant, M. B., ... & Middendorp, S. (2021). A potential treatment of congenital sodium diarrhea in patients with activating GUCY2C mutations. Clinical and Translational Gastroenterology, 12(11).

Jimenez-Luna, C., González-Flores, E., Ortiz, R., Martínez-González, L. J., Antúnez-Rodríguez, A., Expósito-Ruiz, M., ... & Prados, J. (2021). Circulating PTGS2, JAG1, GUCY2C and PGF mRNA in peripheral blood and serum as potential biomarkers for patients with metastatic colon cancer. Journal of Clinical Medicine, 10(11), 2248.

Mathur, D., Root, A. R., Bugaj-Gaweda, B., Bisulco, S., Tan, X., Fang, W., ... & Sapra, P. (2020). A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal CancersA GUCY2C-CD3 Bispecific Targets Gastrointestinal Cancers. Clinical Cancer Research, 26(9), 2188-2202.

Snook, A. E., Baybutt, T. R., Xiang, B., Abraham, T. S., Flickinger, J. C., Hyslop, T., ... & Waldman, S. A. (2019). Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. Journal for ImmunoTherapy of Cancer, 7(1), 1-12.

Merlino, D. J., Barton, J. R., Charsar, B. A., Byrne, M. D., Rappaport, J. A., Smeyne, R. J., ... & Waldman, S. A. (2019). Two distinct GUCY2C circuits with PMV (hypothalamic) and SN/VTA (midbrain) origin. Brain Structure and Function, 224, 2983-2999.

Magee, M. S., Abraham, T. S., Baybutt, T. R., Flickinger Jr, J. C., Ridge, N. A., Marszalowicz, G. P., ... & Snook, A. E. (2018). Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases. Cancer immunology research, 6(5), 509-516.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Human Anti-GUCY2C Recombinant Antibody (
2E5)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Mouse Anti-GUCY2C Recombinant Antibody (3D5) (CAT#: CBMAB-G5791-LY)

Mouse Anti-GUCY2C Recombinant Antibody (1B11) (CAT#: CBMAB-G5784-LY)

Mouse Anti-GUCY2C Recombinant Antibody (1E1) (CAT#: CBMAB-G0938-LY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry